Lynparza, Keytruda Supplemental Indications Face US FDA Panel Review
AstraZeneca and Merck seek to add a pancreatic cancer indication for olaparib, while Merck has hopes of broadening pembrolizumab’s use in bladder cancer; two-day Oncologic Drugs Advisory Committee meeting also will include reviews of Celgene’s luspatercept in myelodysplastic syndromes-related anemia and Epizyme’s tazemetostat for epithelioid sarcoma.
You may also be interested in...
Keeping Track: Vascepa Adds CV Risk Reduction Claim, Vyondys 53 Get A Stunning Approval, And Submissions Pour Into FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.